Connect with us

Markets & Industry

Psych Capital to acquire Shortwave Pharma, addressing demand for eating disorder treatments

Psych Capital has stated that the acquisition aligns with its commitment to improving patient care and advancing mental healthcare through innovative treatments.



Psych Capital to acquire Shortwave Pharma, addressing demand for eating disorder treatments

Global investment firm Psych Capital has agreed to acquire 100% of the issued share capital of Shortwave Pharma Inc., a biopharmaceutical company developing breakthrough psychedelics-based medicines to address unmet medical needs, particularly in the field of eating disorders.

Eating disorders, including; anorexia nervosa, bulimia nervosa and binge-eating disorder, affect millions of individuals worldwide. 

According to the World Health Organisation, it is estimated that approximately 9% of the global population suffers from an eating disorder, highlighting a pressing need for innovative and effective treatments.

Innovating eating disorder treatments

Shortwave Pharma, an Ontario-registered company with operations based in Israel, is currently developing a transformative therapy for treatment-resistant anorexia nervosa – the most fatal eating disorder. 

The company has developed a novel delivery method and drug combination for its initial eating disorders programme for anorexia nervosa, which it states is aimed at maximizing biological activity while being cognizant of low tolerance threshold to psychedelic components. 

See also  PSYCH Symposium returns to the European capital for psychedelic healthcare

Having already completed the preliminary early-stage activities demonstrating the chemistry, manufacturing and controls (CMC) and preclinical abilities of its drug delivery product, the final product meets regulatory requirements for the early phases of clinical studies. 

Shortwave Pharma has stated that the preclinical programme demonstrated not only the safety profile of the drug, but also the ability of its product to bring the active ingredients to the blood without the first pass metabolism. The company believes this will dramatically improve the efficacy of the drug and allow for a better safety profile.

See also  What to expect at PSYCH Symposium 2023

Pre-clinical studies are currently being carried out to complete the profiling of the drug, which should support the design of upcoming clinical studies later this year.

Accelerating drug development

The acquisition of Shortwave Pharma by Psych Capital Plc, which specialises in the field of healthcare, positions the combined entity as a leading player in the field of eating disorder treatments. 

By leveraging Shortwave Pharma’s expertise in drug development in combination with Psych Capital’s extensive resources and global network, as well as its commitment to innovation, the partnership aims to accelerate the development of novel therapies and address the urgent needs of patients suffering from these critical illnesses. 

William Potts, Chief Information Officer (CIO) of Psych Capital Plc, emphasised the importance of this acquisition, stating: “The acquisition of Shortwave Pharma represents a significant step forward in our mission to improve the lives of individuals affected by mental illnesses, such as eating disorders. 

“With their scientific prowess and innovative approach to drug development, we are well-positioned to make meaningful advancements in this critical area of healthcare. 

“The market opportunity for eating disorder treatments is substantial, and there is a pressing need for effective therapies that can address the complex nature of these disorders.”

The acquisition is subject to customary closing conditions and regulatory approvals.

Upon completion of the deal, Rivki Stern Youdkevich, CEO of Shortwave Pharma, will join Psych Capital as CEO and as a board member. The Warrantors of Shortwave Pharma have the right to nominate an additional board director of Psych Capital within six months of the Completion Date, subject to background or regulatory checks as required by the AQUIS adviser. 

Co-founder and CEO at Shortwave Pharma, Rivki Stern has over two decades of entrepreneurial, financial, and hands-on management experience in life sciences and biotech, consumer goods and services Rivki is a CPA (Isr.) and MBA with vast experience in strategy and business development in the US, Europe and Asia.  

In recent years, Stern led go-public processes on exchanges including NASDAQ, IMCC, CSE and IMCC, and has raised over $30 million for cannabis and biotech companies in the fields of diagnostics, therapeutics and clinical development. 

Rivki was a member of boards of Israeli governmental companies, private bio-pharma companies, and currently serves as a consultant to the Israeli government, as well as to accelerator programmes and investment funds. Stern is also a member of the executive management committee at the University of Haifa.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more



Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine



Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Markets & Industry

Short Wave Pharma: innovating eating disorder care with psychedelics



Short Wave Pharma: innovating eating disorder care psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity. 

See also  Psych Capital completes acquisition of Short Wave Pharma

The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.

“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID. 

“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.

“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”

The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain. 

The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability. 

“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern. 

The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place. 

Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.

Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.

Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences. 

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study. 

“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process. 

“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.  

“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”

Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.

Continue Reading